Ahead of President Trump's anticipated announcement on drug pricing, the US Trade Representative released its annual report admonishing US trading partners deemed to have inadequate intellectual property rights protection. A major focus this year is on pricing and reimbursement policies for pharmaceutical products.
But while the spotlight in the US is on reducing drug prices, the USTR's2018 Special 301 Report criticizes countries...





